🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

217 results for “Merck Sharp and Dohme” Clear

  1. Placebo for MK-7240, tulisokibart

    Merck Sharp and Dohme

    Radiographic axial spondyloarthritis (as known as ankylosing spondylitis)

    phase 2 small molecule active

    1 trial

  2. Placebo to ISL, Placebo to MK-8507, Placebo to BIC/FTC/TAF, EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, islatravir, ulonivirine

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 2 small molecule active

    1 trial

  3. Placebo to MK-1167, MK-1167, MK-1167, MK-1167

    Merck Sharp and Dohme

    Alzheimer’s disease dementia

    phase 2 small molecule active

    1 trial

  4. Placebo to MK-6194, MK-6194

    Merck Sharp and Dohme

    Non segmental vitiligo

    phase 2 small molecule active

    1 trial

  5. Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion, mRNA-4157

    Merck Sharp and Dohme

    Melanoma

    phase 2 small molecule active

    1 trial

  6. SOTATERCEPT, SOTATERCEPT, sotatercept, sotatercept

    Merck Sharp and Dohme

    Pulmonary Hypertension

    phase 2 small molecule active

    1 trial

  7. SOTATERCEPT, sotatercept

    Merck Sharp and Dohme

    Pulmonary arterial hypertension

    phase 2 small molecule active

    1 trial

  8. SOTATERCEPT, sotatercept, sotatercept, SOTATERCEPT

    Merck Sharp and Dohme

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule active

    1 trial

  9. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Tepotinib

    Merck Sharp and Dohme

    Lung Cancer

    phase 2 small molecule active

    1 trial

  10. TRETINOIN, gebasaxturev, MK-4280A, vibostolimab, MK-4830, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Stage IIIB or IIIC or IIID melanoma

    phase 2 small molecule active

    1 trial

  11. Tepotinib

    Merck Sharp and Dohme

    Lung Cancer

    phase 2 small molecule active

    1 trial

  12. XL092, XL092, XL092, XL092, Belzutifan

    Merck Sharp and Dohme

    Clear cell renal cell carcinoma

    phase 2 small molecule active

    1 trial

  13. Zilovertamab vedotin

    Merck Sharp and Dohme

    Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults

    phase 2 small molecule active

    1 trial

  14. efinopegdutide, efinopegdutide, efinopegdutide, Placebo to MK-6024, efinopegdutide

    Merck Sharp and Dohme

    Metabolic Dysfunction-Associated Steatohepatitis

    phase 2 small molecule active

    1 trial

  15. favezelimab, quavonlimab, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib

    Merck Sharp and Dohme

    Stage IV non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  16. mRNA-4157, BCG VACCINE

    Merck Sharp and Dohme

    Bladder cancer

    phase 2 small molecule active

    1 trial

  17. rolistobart, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL , CARBOPLATIN , MK-4830, MK-4830, PEMETREXED , boserolimab, vibostolimab

    Merck Sharp and Dohme

    non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  18. rolistobart, MK-4830, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4830

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  19. rolistobart, boserolimab, MK-4830, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4830

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  20. sotatercept, SOTATERCEPT, sotatercept, SOTATERCEPT

    Merck Sharp and Dohme

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule active

    1 trial

  21. tulisokibart, Placebo to MK-7240

    Merck Sharp and Dohme

    Psoriatic arthritis​​

    phase 2 small molecule active

    1 trial

  22. tulisokibart, Placebo to MK-7240 (tulisokibart)

    Merck Sharp and Dohme

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  23. A Multiple-Ascending-Dose Study of MK-1708 in Healthy Participants

    Merck Sharp and Dohme

    Amyotrophic lateral sclerosis and Alzheimer’s disease

    phase 1 other active

    1 trial

  24. A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid Tumors

    Merck Sharp and Dohme

    Breast Cancer, Cervical squamous cell carcinoma, Endometrial Carcinoma, Esophageal squamous cell carcinoma, Head and neck squamous cell carcinoma, Bladder Cancer

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources